Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

64.19 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’ ↗

September 02, 2025

Via Stocktwits

Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion ↗

September 02, 2025

Arrowhead Pharmaceuticals and Novartis inked a licensing deal Tuesday for an experimental Parkinson's drug.

Via Investor's Business Daily

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

September 02, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement ↗

July 23, 2025

Via Stocktwits

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

August 27, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week ↗

August 14, 2025

H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday.

Via Stocktwits

Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives ↗

August 14, 2025

Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquified its entire stake in the company.

Via Investor's Business Daily

Topics Death

Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial ↗

August 14, 2025

Sarepta sold part of its Arrowhead stake to help fund the milestone payment, while also outlining plans to release early data from two genetic therapy programs in the second half of 2025.

Via Stocktwits

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

August 13, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead (ARWR) Q3 2025 Earnings Call Transcript ↗

August 07, 2025

Via The Motley Fool

Topics Earnings

Arrowhead (ARWR) Q3 Revenue Drops 41% ↗

August 07, 2025

Via The Motley Fool

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Reports Mixed Q3 2025 Results with Revenue Beat but Wider-Than-Expected Loss ↗

August 07, 2025

Arrowhead Pharmaceuticals reported mixed Q3 2025 results, beating revenue estimates but missing on EPS. Stock fell 5.3% as higher R&D costs widened losses. Key pipeline updates include plozasiran NDA...

Via Chartmill

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

August 07, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

August 01, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On? ↗

July 29, 2025

Stock of Sarepta Therapeutics Inc. (NASDAQ: SRPT) surged 38.89% in Tuesday pre-market following the U.S. Food and Drug Administration's (FDA) recommendation to lift the voluntary hold on Elevidys,...

Via Benzinga

FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys ↗

July 28, 2025

FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment.

Via Benzinga

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

July 28, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy ↗

July 25, 2025

Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.

Via Benzinga

Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe ↗

July 25, 2025

Shares are down another double-digit percentage after bad news continued piling on for gene therapy Elevidys.

Via Investor's Business Daily

Topics Death

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

July 24, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday ↗

July 23, 2025

Via Benzinga

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

July 23, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review ↗

July 22, 2025

Sarepta pauses U.S. Elevidys shipments to complete FDA-requested safety label updates, aiming to resume distribution in the fourth quarter.

Via Benzinga

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

July 21, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

July 08, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

June 23, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses' ↗

June 04, 2025

Arrowhead Pharmaceuticals, Snowflake, Dover and Fluor are each in focus on today's edition of "Mad Money Lightning Round."

Via Benzinga

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

June 02, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.